SRES-416-119
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S6798; text: CR S6795)
Sponsored by Tim Scott (R-SC)
What it does
This resolution expresses the Senate's support for designating September 2025 as "Sickle Cell Disease Awareness Month." It does not create any new programs, allocate funding, or impose any legal requirements. It encourages public education about sickle cell disease, including the need for research, early detection, effective treatments, and preventative care.
Who benefits
The approximately 100,000 Americans living with sickle cell disease — a population that is disproportionately Black or African American — may benefit from increased public awareness. Patient advocacy organizations focused on sickle cell disease may gain visibility. Researchers and clinicians working on sickle cell treatments could see increased public interest in their work. Families of affected individuals may benefit from broader community understanding of the disease.
Who is hurt
No group faces a direct material cost or legal burden from this resolution. Because it carries no funding or mandates, it does not redirect resources from other disease awareness efforts or programs.
Supporters argue
Supporters argue that sickle cell disease affects roughly 100,000 Americans and that awareness campaigns are a low-cost, high-visibility tool for encouraging early screening and diagnosis, which can meaningfully reduce complications. They contend that formal congressional recognition signals national commitment to a condition that has historically received less research funding relative to diseases of comparable prevalence, and that awareness months have been associated with increased patient advocacy and community engagement.
Opponents argue
Opponents argue that symbolic resolutions consume limited legislative floor time without producing measurable health outcomes, and that the Senate's attention would be better directed toward substantive legislation — such as increased NIH funding or expanded newborn screening mandates — that would materially improve care for sickle cell patients. They contend that awareness designations have proliferated to the point where their marginal impact on public attention or research investment is difficult to demonstrate empirically.